Article

Preclinical evaluation of RQ3013, a broad-spectrum mRNA vaccine against SARS-CoV-2 variants

2022-05-10

Abstract excerpt

The global emergence of SARS-CoV-2 variants has led to increasing breakthrough infections in vaccinated populations, calling for an urgent need to develop more effective and broad-spectrum vaccines to combat COVID-19. Here we report the preclinical development of RQ3013, an mRNA vaccine candidate intended to bring broad protection against SARS-CoV-2 variants of concern (VOCs). RQ3013, which contains pseudouridine-...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e4e2551e-92b8-538a-93f4-fab5bae981c7
DOI: 10.1101/2022.05.10.491301

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Preclinical evaluation of RQ3013, a broad-spectrum mRNA vaccine against SARS-CoV-2 variantsDOI 10.1101/2022.05.10.491301Read

A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical modelsSemantic proximity Read

Effectiveness of a broad-spectrum bivalent mRNA vaccine against SARS-CoV-2 variants in preclinical studiesSemantic proximity Read

Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal modelsSemantic proximity Read

saRNA vaccine expressing membrane-anchored RBD elicits broad and durable immunity against SARS-CoV-2 variants of concernSemantic proximity Read

mRNA-delivered neutralizing antibodies confer protection against SARS-CoV-2 variant in the lower and upper respiratory tractSemantic proximity Read

Durable cross-protective neutralizing antibody responses elicited by lipid nanoparticle-formulated SARS-CoV-2 mRNA vaccinesSemantic proximity Read

Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-BSemantic proximity Read

RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge.Semantic proximity Read

Development of SARS-CoV-2 mRNA vaccines encoding spike N-terminal and receptor binding domainsSemantic proximity Read

Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2Semantic proximity Read

SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen PreparednessSemantic proximity Read

A Broad-Spectrum Multi-Antigen mRNA/LNP-Based Pan-Coronavirus Vaccine Induced Potent Cross-Protective Immunity Against Infection and Disease Caused by Highly Pathogenic and Heavily Spike-Mutated SARS-CoV-2 Variants of Concern in the Syrian Hamster ModelSemantic proximity Read